342 related articles for article (PubMed ID: 34774104)
1. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
2. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
3. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
[TBL] [Abstract][Full Text] [Related]
4. Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Yaseri M; Hosseinzadeh-Attar MJ
Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):345-353. PubMed ID: 34860705
[TBL] [Abstract][Full Text] [Related]
5. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.
Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
Trials; 2018 Nov; 19(1):634. PubMed ID: 30445988
[TBL] [Abstract][Full Text] [Related]
6. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
[TBL] [Abstract][Full Text] [Related]
7. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
[TBL] [Abstract][Full Text] [Related]
8. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
BMJ Open; 2017 Jul; 7(7):e016914. PubMed ID: 28698350
[TBL] [Abstract][Full Text] [Related]
10. Effect of a moderately carbohydrate-restricted diet on liver enzymes, steatosis and fibrosis in normal-weight individuals with non-alcoholic fatty liver disease: study protocol for a parallel randomised controlled clinical trial.
Dashti F; Alavian SM; Sohrabpour AA; Mousavi SE; Keshavarz SA; Esmaillzadeh A
BMJ Open; 2023 Apr; 13(4):e063988. PubMed ID: 37117000
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, and inflammatory and antioxidant biomarkers in overweight or obese prediabetic patients: a study protocol for a randomized double-blind placebo-controlled phase 2 clinical trial.
Karandish M; Mozaffari-Khosravi H; Mohammadi SM; Azhdari M; Cheraghian B
Trials; 2020 Nov; 21(1):991. PubMed ID: 33256795
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: a Double-Blind, Randomized Placebo-Controlled Trial.
Fathi M; Alavinejad P; Haidari Z; Amani R
Biol Trace Elem Res; 2020 Oct; 197(2):394-404. PubMed ID: 32020523
[TBL] [Abstract][Full Text] [Related]
13. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
Wicklow B; Wittmeier K; T' Jong GW; McGavock J; Robert M; Duhamel T; Dolinsky VW
Biochem Cell Biol; 2015 Oct; 93(5):522-30. PubMed ID: 26305052
[TBL] [Abstract][Full Text] [Related]
14. The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
Fathi M; Alavinejad P; Haidari Z; Amani R
J Trace Elem Med Biol; 2020 Dec; 62():126635. PubMed ID: 32932174
[TBL] [Abstract][Full Text] [Related]
15. Study protocol of a randomized controlled clinical trial investigating the effects of omega-3 supplementation on endothelial function, vascular structure, and metabolic parameters in adolescents with type 1 diabetes.
Khorshidi M; Sayyari A; Olang B; Alaei MR; Shab-Bidar S; Khalili M; Salehi M; Aryaeian N
Trials; 2021 Dec; 22(1):953. PubMed ID: 34961564
[TBL] [Abstract][Full Text] [Related]
16. The effects of intermittent fasting diet alone or in combination with probiotic supplementation in comparison with calorie-restricted diet on metabolic and hormonal profile in patients with polycystic ovary syndrome: study protocol for a randomized clinical trial.
Talebi S; Shab-Bidar S; Mohammadi H; Moini A; Djafarian K
Trials; 2023 Oct; 24(1):690. PubMed ID: 37880791
[TBL] [Abstract][Full Text] [Related]
17. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease.
Naeini F; Namkhah Z; Ostadrahimi A; Tutunchi H; Hosseinzadeh-Attar MJ
Adv Nutr; 2021 Mar; 12(2):413-428. PubMed ID: 32879962
[TBL] [Abstract][Full Text] [Related]
19. The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: a randomized double-blind controlled trial.
Vahedi H; Atefi M; Entezari MH; Hassanzadeh A
Trials; 2022 Jul; 23(1):551. PubMed ID: 35804451
[TBL] [Abstract][Full Text] [Related]
20. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
